ExpreS2ion Biotechnologies Overview
- Year Founded
-
2010
- Status
-
Public
- Employees
-
19
- Stock Symbol
-
EXPRS2
- Investments
-
1
- Share Price
-
$0.08
- (As of Friday Closing)
ExpreS2ion Biotechnologies General Information
Description
ExpreS2ion Biotech Holding AB has developed a technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. The company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with research institutions and companies.
Contact Information
Website
www.expres2ionbio.comCorporate Office
- Agern Alle 1
- 2970 Horsholm
- Denmark
Corporate Office
- Agern Alle 1
- 2970 Horsholm
- Denmark
ExpreS2ion Biotechnologies Timeline
ExpreS2ion Biotechnologies Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.08 | $0.08 | $0.06 - $0.48 | $7.03M | 83.6M | 305K | -$0.08 |
ExpreS2ion Biotechnologies Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 964 | 3,983 | 46,140 | 110,644 |
| Revenue | 424 | 663 | 501 | 1,425 |
| EBITDA | (4,631) | (9,387) | (12,459) | (5,347) |
| Net Income | (4,262) | (8,599) | (11,691) | (5,115) |
| Total Assets | 8,838 | 7,874 | 13,168 | 16,791 |
| Total Debt | 34 | 171 | 177 | 233 |
ExpreS2ion Biotechnologies Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ExpreS2ion Biotechnologies Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
ExpreS2ion Biotechnologies Patents
ExpreS2ion Biotechnologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220112535-A1 | Production of protein with humanized n-glycosylation in insect cells | Pending | 10-Jan-2019 | 0000000000 | |
| EP-3908655-A1 | Production of protein with humanized n-glycosylation in insect cells | Pending | 10-Jan-2019 | 0000000000 | |
| CA-3125812-A1 | Production of protein with humanized n-glycosylation in insect cells | Pending | 10-Jan-2019 | 0000000000 | |
| EP-3908302-A1 | Glyco-engineered immunization antigens | Pending | 10-Jan-2019 | 000000000 | |
| US-20220111027-A1 | Glyco-engineered immunization antigens | Active | 10-Jan-2019 | A61K45/06 | 0 |
ExpreS2ion Biotechnologies Executive Team (8)
| Name | Title | Board Seat |
|---|---|---|
| Bent Frandsen | Chief Executive Officer | |
| Keith Alexander | Chief Financial Officer | |
| Farshad Guirakhoo Ph.D | Chief Scientific Officer |
ExpreS2ion Biotechnologies Board Members (6)
| Name | Representing | Role | Since |
|---|---|---|---|
| Jakob Knudsen | Self | Board Member | 000 0000 |
| Martin Jensen Ph.D | Self | Chairman & Board Member | 000 0000 |
ExpreS2ion Biotechnologies Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
ExpreS2ion Biotechnologies Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
ExpreS2ion Biotechnologies Investments (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| AdaptVac | 21-Jun-2017 | 00000 0000 | Biotechnology | 00000 000 |
ExpreS2ion Biotechnologies ESG
Risk Overview
Risk Rating
Updated November, 01, 2023
28.96 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 16,009
Rank
Percentile
Pharmaceuticals
Industry
00 of 909
Rank
Percentile
Biotechnology
Subindustry
00 of 404
Rank
Percentile
ExpreS2ion Biotechnologies FAQs
-
When was ExpreS2ion Biotechnologies founded?
ExpreS2ion Biotechnologies was founded in 2010.
-
Who is the founder of ExpreS2ion Biotechnologies?
Charlotte Dyring Ph.D and Wian Jongh Ph.D are the founders of ExpreS2ion Biotechnologies.
-
Who is the CEO of ExpreS2ion Biotechnologies?
Bent Frandsen is the CEO of ExpreS2ion Biotechnologies.
-
Where is ExpreS2ion Biotechnologies headquartered?
ExpreS2ion Biotechnologies is headquartered in Horsholm, Denmark.
-
What is the size of ExpreS2ion Biotechnologies?
ExpreS2ion Biotechnologies has 19 total employees.
-
What industry is ExpreS2ion Biotechnologies in?
ExpreS2ion Biotechnologies’s primary industry is Drug Discovery.
-
Is ExpreS2ion Biotechnologies a private or public company?
ExpreS2ion Biotechnologies is a Public company.
-
What is ExpreS2ion Biotechnologies’s stock symbol?
The ticker symbol for ExpreS2ion Biotechnologies is EXPRS2.
-
What is the current stock price of ExpreS2ion Biotechnologies?
As of 06-Sep-2024 the stock price of ExpreS2ion Biotechnologies is $0.08.
-
What is the current market cap of ExpreS2ion Biotechnologies?
The current market capitalization of ExpreS2ion Biotechnologies is $7.03M.
-
What is ExpreS2ion Biotechnologies’s current revenue?
The trailing twelve month revenue for ExpreS2ion Biotechnologies is $424K.
-
What is ExpreS2ion Biotechnologies’s annual earnings per share (EPS)?
ExpreS2ion Biotechnologies’s EPS for 12 months was -$0.08.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
